Resource Summary Report

Generated by RRID on Sep 10, 2026

U.S. Food and Drug Administration

RRID:SCR_012945
Type: Tool

Proper Citation

U.S. Food and Drug Administration (RRID:SCR_012945)

Resource Information

URL: http://www.fda.gov/

Proper Citation: U.S. Food and Drug Administration (RRID:SCR_012945)

Description: An agency of the United States Department of Health and Human Services, one of the United States federal executive departments that is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics and veterinary products. The FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs. These include sanitation requirements on interstate travel and control of disease on products ranging from certain household pets to sperm donation for assisted reproduction. (Wikipedia)

Abbreviations: FDA, USFDA

Synonyms: U.S. FDA, US FDA, US Food and Drug Administration, Food and Drug Administration, United States Food and Drug Administration

Resource Type: institution

Resource Name: U.S. Food and Drug Administration

Resource ID: SCR_012945

Alternate IDs: grid.417587.8, nlx_inv_1005074, ISNI: 0000 0001 2243 3366, Wikidata: Q204711, Crossref funder ID: 100000038

Alternate URLs: https://ror.org/034xvzb47

Record Creation Time: 20220129T080313+0000

Record Last Update: 20260905T132729+0000

Ratings and Alerts

No rating or validation information has been found for U.S. Food and Drug Administration.

No alerts have been found for U.S. Food and Drug Administration.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 1963 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Mart??-Carvajal AJ, et al. (2026) Percutaneous coronary intervention plus guideline-directed medical therapy (GDMT) versus GDMT alone in adults with stable coronary artery disease. The Cochrane database of systematic reviews, 1(1), CD016213.

Gu WG, et al. (2026) Advancements in development of novel class of HIV protease inhibitors. Annals of medicine, 58(1), 2617730.

Tang B, et al. (2026) Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study. CNS neuroscience & therapeutics, 32(1), e70747.

Iglesias-Lopez C, et al. (2026) Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Therapeutic innovation & regulatory science, 60(3), 823.

Wen Z, et al. (2026) The Real-World Safety Profile of Temazepam: A 20-Year Pharmacovigilance Analysis Based on the Large-Scale FAERS Database. CNS neuroscience & therapeutics, 32(3), e70836.

Wang Q, et al. (2026) Smart responsive hydrogels combined with AI design for tumor therapy. Acta pharmaceutica Sinica. B, 16(6), 3425.

Zhu N, et al. (2026) A systematic review of immune checkpoint inhibitors in endometrial cancer. Frontiers in oncology, 16, 1776831.

Poolchanuan P, et al. (2026) Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022). Scientific reports, 16(1), 3408.

Song H, et al. (2026) Emergence of Polymyxin Resistance Driven by a PhoQ Mutation in KPC-2-Producing Klebsiella pneumoniae. Antibiotics (Basel, Switzerland), 15(2).

Wu D, et al. (2026) Establishment and application of China's first pediatric rational medication intelligent decision system database. Frontiers in pediatrics, 14, 1736268.

Liang C, et al. (2026) Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology. PloS one, 21(3), e0343084.

Liu H, et al. (2026) Single-Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re-Sensitizer Drugs in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(29), e13246.

Shrimali S, et al. (2026) Exposure to a Titanium Dioxide Product Alters MicroRNA Expression in Human Cells. Toxics, 14(4).

Zhang P, et al. (2026) Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases. Therapeutic advances in drug safety, 17, 20420986261454180.

Feldman K, et al. (2026) Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention. Cancer research communications, 6(6), 1486.

Colli A, et al. (2026) Quantification of Alpha-Gal Expression in Commercial BioProsthetic Heart Valves and Its Potential Mitigation. Structural heart : the journal of the Heart Team, 10(3), 100739.

Wang Q, et al. (2026) Novel ST3871 Escherichia coli exhibits diverse transmission modes, carrying the tet(X4) resistance gene. Microbiology spectrum, 14(3), e0052125.

Xu R, et al. (2026) Safety profile of progesterone: Insights from an FDA Adverse Event Reporting System (FAERS)-based pharmacovigilance study. The Journal of international medical research, 54(2), 3000605261417447.

Guellil I, et al. (2026) Detecting Adverse Drug Events in Social Media: A Brief Literature Review. SN computer science, 7(2), 199.

Tian Y, et al. (2026) Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients. Thoracic cancer, 17(6), e70263.